论文部分内容阅读
1995年美国临床肿瘤学会（ASCO）会议报道了许多新治疗战略的I期临床试验结果。初步试验只观察到少数副作用，表现趋向研究效价的进展。有最大兴趣的是两个基因治疗，即Vieal公司Allovectin－7和So－matix公司GVAX，研究结果表明，Allovectin－7和GVAX没有任何副作用，现已扩展
The 1995 American Society of Clinical Oncology (ASCO) meeting reported a number of new treatment strategies in Phase I clinical trial results. Preliminary trials observed only a few side effects and tended to study the progress of potency. Of particular interest are two gene therapies, Voveal Allovectin-7 and Somatrix’s GVAX, which show that Allovectin-7 and GVAX have no side effects and are now expanded